engage checkpoint medical linkedin twitter

Update on key HCC data presented at ASCO GI and EASL-LCS 2022

Update on key HCC data presented at ASCO GI and EASL-LCS 2022

Prof. James Harding

Professor James Harding provides insights on key topics and abstracts in HCC presented at ASCO GI and EASL-LCS 2022.

Portrait of James Harding
Prof. James Harding

Medical Oncologist

Memorial Sloan Kettering Cancer Center

United States (US)

preview next

time Podcast | open 15 min | Feb 2022

Subscribe to our podcast series on:

download resources

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimem, respectively

HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer, AstraZeneca and from Eisai Europe Limited.

Other programmes of interest